Analyst Price Target is $53.25
▲ +335.05% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $53.25, with a high forecast of $90.00 and a low forecast of $15.00. The average price target represents a 335.05% upside from the last price of $12.24.
Current Consensus is
Moderate Buy
The current consensus among 7 investment analysts is to moderate buy stock in Biomea Fusion. This Moderate Buy consensus rating has held steady for over two years.
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More